

19 **THE PROTOCOL**

20 **EDITORIAL SUMMARY [AU: This is used to summarise your protocol on the website (up to 250
21 characters including spaces). Please check – are these the most important points that you
22 would like to make? Currently = 246 characters]**

23 Evaluating the metabolic organisation of complex tissue microenvironments is useful for
24 understanding cellular function within tissues. This protocol describes a multimodal imaging
25 pipeline for cell type identification and stable isotope imaging.

26

27 **A Multimodal Imaging Pipeline to Decipher Cell-Specific Metabolic Functions
28 and Tissue Microenvironment Dynamics**

29 Sharavan Vishaan Venkateswaran¹, Peter Kreuzaler^{1,3}, Catherine MacLachlan¹, Greg McMahon²,
30 Gina Greenidge², Lucy Collinson¹, Josephine Bunch², Mariia Yuneva¹.

31 ¹The Francis Crick Institute, London, UK

32 ²The National Physical Laboratory, Teddington, UK

33 ³University of Cologne, Faculty of Medicine and University Hospital Cologne, Cluster of Excellence Cellular Stress
34 Responses in Aging-associated Diseases (CECAD), Cologne, Germany.

35 These authors contributed equally: Sharavan Vishaan Venkateswaran, Peter Kreuzaler.

36 Correspondence to: sharavan.venkateswaran@crick.ac.uk; peter.kreuzaler@uni-koeln.de;
37 mariia.yuneva@crick.ac.uk.

38

39 **Key points [AU:** These are used to summarise your protocol on the pdf version. Please check
40 that these are the main points that you would like to highlight. Max word count = 66. Currently
41 = xx.]

42 • To understand complex tissues, it is useful to map metabolic processes to specific cell
43 types.

44 • Nanoscale secondary ion mass spectrometry (NanoSIMS) can differentiate between
45 isotopes derived from labeled metabolites at sub-cellular resolution.

46 • This protocol combines three imaging modalities: confocal microscopy of fluorescent
47 probes (antibodies); electron microscopy; and NanoSIMS enabling cell type identification,
48 characterization of the cellular architecture, and extraction of metabolic information.

49

50 **Key references** [Up to 5 articles relevant to this protocol; where the method has been
51 introduced and/or used. Repeat these under the Related links headings. Use the formatting
52 shown in the example below.]

53 de Boer, P., Hoogenboom, J. P. & Giepmans, B. N. G. Correlated light and electron microscopy:
54 ultrastructure lights up! *Nat Methods* 12, 503–513 (2015): <https://doi.org/10.1038/nmeth.3400>

55 Lechene, C. P., Luyten, Y., McMahon, G. & Distel, D. L. Quantitative Imaging of Nitrogen Fixation
56 by Individual Bacteria Within Animal Cells. *Science* (1979) 317, 1563–1566 (2007):
57 <https://www.science.org/doi/10.1126/science.1145557>

58 Greenwood, D. J. et al. Subcellular antibiotic visualization reveals a dynamic drug reservoir in
59 infected macrophages. *Science* (1979) 364, 1279–1282 (2019):
60 <https://www.science.org/doi/10.1126/science.aat9689>

61 **Key data used in this protocol**

62 Kreuzaler, P. et al. Vitamin B5 supports MYC oncogenic metabolism and tumor progression in
63 breast cancer. *Nat Metab* 5, 1870–1886 (2023): <https://doi.org/10.1038/s42255-023-00915-7>

64

65 **[H1] Abstract**

66 Tissue microenvironments are extremely complex and heterogenous. It is challenging to study
67 metabolic interaction between the different cell types in a tissue with the techniques that are

68 currently available. In this paper we describe a multimodal imaging pipeline that allows cell
69 type identification and nanoscale tracing of stable isotope labelled compounds. This pipeline
70 extends upon the principles of correlative light, electron, and ion microscopy (CLEIM), by
71 combining confocal microscopy reporter or probe-based fluorescence, electron microscopy
72 (EM), stable isotope labelling and Nanoscale secondary ion mass spectrometry (NanoSIMS). We
73 apply this method to murine models of hepatocellular and mammary gland carcinomas to study
74 uptake of glucose derived carbon (^{13}C) and glutamine derived nitrogen (^{15}N) by tumour
75 associated immune cells. *In vivo* labelling with fluorescent-tagged antibodies (B220, CD3, CD8a,
76 CD68) in tandem with confocal microscopy allows for the identification of specific cell types (B
77 cells, T cells and macrophages) in the tumour microenvironment (TME). Subsequent image
78 correlation with electron microscopy offers the contrast and resolution to image membranes
79 and organelles. NanoSIMS tracks the enrichment of stable isotopes within these intracellular
80 compartments. The whole protocol described here would take approximately 6 weeks to
81 perform from start to finish. Our pipeline caters to a broad spectrum of applications, as it can
82 easily be adapted to trace the uptake and utilisation of any stable isotope labelled nutrient,
83 drug, or a probe by defined cellular populations in any tissue *in situ*.

84

85 **[H1] Introduction**

86 **[H2] Development of the protocol**

87 Metabolism is one of the most fundamental aspects of cellular biology, enabling the chemical
88 fluxes to generate energy, whilst providing the building blocks for all biomolecules needed in

89 cell maintenance and propagation. Evaluating the metabolic organisation of complex tissue
90 microenvironments and dissecting interactions between their components is thus vital to
91 decipher cellular function, understand disease mechanisms and design efficient therapeutic
92 approaches. Yet, there is a distinct lack of comprehensive imaging methods for pinpointing
93 metabolic activities in specific cell types at a subcellular level. Our pipeline addresses this gap
94 using a multimodal imaging approach which leverages the strength of pre-existing individual
95 modalities¹.

96 Our pipeline builds on established methods: mainly the correlative light, electron microscopy
97 (CLEM) reported by MacLachlan et al.², as well as the combination with secondary ion mass
98 spectrometry (CLEIM) presented by Fearn et al.³ and de Boer et al.⁴. Injection of fluorescent
99 antibodies was modelled on mouse studies utilising these methods^{5,6}, but adapted for our
100 purposes and made compatible with commercially available antibodies. Administration of
101 labelled metabolites was adapted following our own protocols such as those outlined in
102 Mendez et al.⁷. Work done by Quinn et al⁸ integrates NanoSIMS with transmission electron
103 microscopy (TEM), while Lechene et al⁹ published a method that utilises multi-isotope imaging
104 mass spectrometry (MIMS) in combination with TEM. However, both these methods do not
105 utilise correlative light microscopy, which is essential for identifying different cell populations
106 within a complex tissue microenvironment. The approach by Loussert-Fonta et al¹⁰, based on
107 CLEIM, has a lot of similarities to the protocol we describe here but also incorporates TEM as
108 opposed to scanning electron microscopy (SEM) which we have utilised. Our protocol, however,
109 offers some key advantages and improvements over these previously published methods for a
110 broad range of applications.

111 SEM provides several benefits over TEM for our purposes. SEM allows imaging of much larger
112 areas, and the elimination of the requirement for electron transparency means more material is
113 available for sputtering. This is particularly important when performing NanoSIMS, because
114 implanting the sample with Cs⁺ from the primary ion beam is required for achieving good
115 ionisation. This process often leaves only a limited amount of sample to sputter for subsequent
116 analysis. When using ¹³C labelling as we do, this can be particularly problematic, especially
117 while looking at small enrichments above natural abundance, as poor counting statistics might
118 impede detection.

119 Additionally, our method better preserves the ultrastructure compared to using cryofixation
120 and TEM (Loussert-Fonta et al¹⁰). This is crucial when examining cellular organelles such as
121 mitochondria. Finally, we combine confocal microscopy with volume electron microscopy (vEM)
122 for the entire tissue section, thereby providing a greater target volume for analysis.

123 There are a few other notable methods employed in the field which are not based on
124 CLEM/CLEIM that have been used to address similar questions, we have listed these in the table
125 below along with their respective advantages and limitations:

126 **Table1: Advantages and limitations of recently developed metabolic profiling methods.**

Method	Advantages	Limitations
SCENITH ¹¹ - Flow Cytometry-Based Method to Functionally Profile Energy Metabolism with Single-Cell Resolution	<ul style="list-style-type: none">• Single cell resolution.• Can profile both abundant and non-abundant cell types in parallel.• Can be used to directly profile	<ul style="list-style-type: none">• Limited insight into metabolic functions of individual cells.• Spatial information of tissue histology is lost.

	metabolism <i>ex vivo</i> from patient samples.	
scMEP ¹² - single-cell metabolic regulome profiling	<ul style="list-style-type: none"> • Single cell resolution. • Robust identification of different cell types. • Imaging-based scMEP allows for study of spatial organisation of cellular metabolism. 	<ul style="list-style-type: none"> • Offers an approximation of metabolic states, cannot be used to study metabolic fluxes.
OrbiSIMS ^{13,14} - Label-free metabolic imaging with subcellular lateral resolution and high mass-resolving power	<ul style="list-style-type: none"> • Single cell resolution • High mass resolving power and high spatial resolution. • Minimal sample preparation. 	<ul style="list-style-type: none"> • Offers better coverage of apolar metabolites. • Cell type identification with IHC cannot be carried out on the same sample.
DESI-MSI + IF ¹⁵ - Cell-Type-Specific Metabolic Profiling by Combining Desorption Electrospray Ionization Mass Spectrometry Imaging and Immunofluorescence Staining	<ul style="list-style-type: none"> • Offers a large coverage of both polar and apolar metabolites. • Can be used to study spatial changes in metabolic fluxes within and across different tissue. 	<ul style="list-style-type: none"> • Relatively low resolution • Not recommended for studying the metabolism of rare cell populations.

127

128 **[H2] Applications of the method**

129 In our original publication¹ we utilised an inducible and traceable model of MYC heterogeneity
 130 in breast cancer which we had previously developed and characterised¹⁶. Briefly, this model
 131 enables the creation of triple-negative mammary tumours driven by WNT1, with the optional
 132 inclusion of a MYC-ERT^{T2} construct. The MYC-ERT^{T2} construct expresses supraphysiological levels
 133 of the MYC-ER fusion protein, which can be activated by tamoxifen administration. Clones
 134 lacking MYC-ERT^{T2} express tdTomato (red clone) as a tracer, while clones containing MYC-ERT^{T2}
 135 express enhanced green fluorescent protein (green clone). Mixing these two clones produces

136 bi-clonal tumours. We initially developed this imaging pipeline to study the metabolic
137 interaction between these two distinct tumour clones in the bi-clonal tumours. Correlative light
138 microscopy was crucial for differentiating the red and green clones within the tumour tissue.
139 The EM provided the necessary contrast and resolution to image membranes and organelles of
140 the tumour cells, while NanoSIMS enabled tracking the enrichment of stable isotopes within
141 these intracellular compartments (Figure 1A)¹.

142 We then aimed to validate whether this protocol could be applied to study the metabolic
143 dynamics of other cell types within the TME that lack a fluorescent tracer expression. To
144 achieve this, we combined our imaging pipeline with the *in vivo* administration of non-depleting
145 fluorescent-tagged antibody (CD68-AF647) to label macrophages in the bi-clonal tumour model
146 (Figure 1B). We were limited to only exploring one additional cell type in this model due to the
147 green and red fluorescent channels being already taken up by the two different tumour clones.
148 The results show the uptake of glucose derived carbon (¹³C) and glutamine derived nitrogen
149 (¹⁵N) by the macrophage (yellow ROI) and surrounding tumour cells (Figure 1C) .

150 To further test the robustness of our protocol, we decided to apply the complete pipeline to a
151 different tumour model, specifically MYC-induced liver tumours⁷. In this model, we examined
152 tumour-resident T and B cells, which were labelled through the *in vivo* administration of non-
153 depleting fluorescent-tagged antibodies (CD3-AF488 for T cells, CD8a-PE for cytotoxic T cells,
154 B220-AF647 for B cells). Figure 2 shows the uptake of glucose derived carbon (¹³C) and
155 glutamine derived nitrogen (¹⁵N) by cytotoxic-T cells (CD8a, red ROI) and B cells (B220, blue
156 ROI). These results successfully demonstrate how our protocol can be expanded and applied to
157 study the metabolic dynamics of different cell types within the TME across two distinct tumour

158 models. We propose that the current iteration of this pipeline can be similarly adapted for
159 various applications, providing valuable insights into cellular interactions within cancer and
160 other research areas that utilise preclinical models.

161 **[H2] Limitations**

162 Fluorescent labelling of the cells is done *in vivo* using fluorescently labelled antibodies. These
163 probes are not able to enter healthy cells, therefore all antibodies must recognise an
164 extracellular epitope.

165 The number of different cell types that can be detected concurrently is limited by the number
166 of fluorophores that can be imaged simultaneously using a confocal microscope; this is usually 3
167 biomarkers plus one nuclear counterstain.

168 The spatial resolution of NanoSIMS typically spans from tens to hundreds of nanometres,
169 defined by the diameter of the primary ion beam used to raster scan and sputter the sample.
170 While this resolution is theoretically adequate for discerning most cell organelles, smaller target
171 organelles or lower metabolite concentrations/ densities will result in a decrease in the
172 quantity of atoms and molecules (measured in yoctomoles) available for ionization within the
173 sub-femtoliter volume under analysis.

174 NanoSIMS sensitivity can be limited and variable as not all atoms and molecules are ionized
175 during the primary beam induced sputter process. A large fraction of these ejected atoms and
176 molecules retains a neutral charge and thus cannot be effectively collected and steered into the
177 mass spectrometer. Consequently, this limitation often leads to a narrowed dynamic range in
178 detection capabilities¹⁷.

179 While NanoSIMS offers organelle level resolution, the technology only allows for measurement
180 of individual atoms or very simple molecules such as C and N, this is due to the chemical
181 fixation which causes loss of soluble components within the cells. When infusing with [U-¹³C]
182 glucose for example, we are only able to measure the isotope ratio of ¹³C/¹²C derived from
183 glucose i.e. we do not get any molecular information about the metabolic conversion of the
184 labelled metabolite.

185 **[H2] Experimental design**

186 **[H3] Choice of antibodies:**

187 The choice of antibodies depends on the tissue that you are interested in studying and the
188 biological question. Previous research has demonstrated that tumour-infiltrating T cells and B
189 cells play a critical role in determining prognosis and guiding therapeutic intervention in
190 hepatocellular carcinoma (HCC)^{18–20}. Based on these studies, we selected antibodies against
191 CD3, CD8a and B220 to , cytotoxic T cells and B cells, respectively, in our MYC-
192 induced liver tumour mouse model.

193 **[H3] Choice of metabolite // choice of isotope**

194 In addition to the results published in Kreuzaler et al¹, in this paper, we further demonstrate the
195 strength of our imaging pipeline by presenting another case study—the spatially resolved
196 incorporation of [U-¹³C] glucose-derived carbon (¹³C) and [amide-¹⁵N] glutamine-derived
197 nitrogen (¹⁵N) into B cells and T cells within the murine liver TME. We chose these metabolites
198 specifically because we and others in the field have previously shown that glucose and
199 glutamine catabolism is increased in MYC-driven tumours ^{7,21}.

200 NanoSIMS can, however, be used to detect any heavy atom (deuterium, ^{18}O , ^{13}C , ^{15}N , etc.).
201 Based on a biological question, a labelled metabolite catabolised through a defined pathway(s)
202 would give a clearer readout for the pathway activity within specific TME compartments.
203 Indeed, we showed that this strategy is effective not only for glucose and glutamine with
204 tracing the incorporation of nitrogen (^{15}N) derived from labelled pantothenic acid (vitamin B₅)
205 in our previous publication¹.

206 **[H3] The *in vivo* experiment**

207 As described earlier, the bi-clonal mammary gland tumour model enables the generation of
208 triple-negative mammary tumours driven by WNT1, with the optional inclusion of a MYC-ER^{T2}
209 construct. To initially generate spontaneous non-recombined tumours as a source of bi-clonal
210 tumours, Rosa26-CAG-lox-STOP-lox-MYC-ER^{T2}/ Rosa26-mTmG/MMTV-Wnt1 mice were used¹⁶.
211 The MYC-ER^{T2} construct expresses supraphysiological levels of the MYC-ER fusion protein,
212 which can be activated by tamoxifen administration. Clones lacking MYC-ER^{T2} express tdTomato
213 (red clone) as a tracer, while clones containing MYC-ER^{T2} express enhanced green fluorescent
214 protein (green clone). Mixing these two clones produces bi-clonal tumours (Figure 1A)¹.
215 MYC-induced liver tumours are generated via hydrodynamic-based transfection to manipulate
216 gene expression in hepatocytes. This is a systemic administration of plasmid DNA in mice,
217 where the plasmids encoding genes of interest are injected through the tail vein²².
218 Once the tumours were generated in both models, the labelled metabolite infusion and
219 antibody injections were performed. Based on our prior experience, we carried out a 3-hour
220 infusion via tail vein for the labelled metabolites to achieve a higher percentage of the label

221 enrichment in a metabolite pool. This also ensures a stronger signal to noise ratio in the
222 NanoSIMS. Tumour resident T and B cells were labelled by non-depleting intravenous (iv) bolus
223 administration of fluorescent-tagged antibodies as specified above.

224 **[H3] Preparing the microscopy samples and data acquisition**

225 The tumours were then extracted, fixed, and cut into slices using a vibratome. Following which,
226 traditional confocal microscopy was used to detect different cell types in the TME (CD3-AF488
227 for T cells, CD8a-PE for cytotoxic T cells, B220-AF647 for B cells and CD68-AF647 for
228 macrophages).

229 The tissue slices were then prepared for vEM, and the confocal stack was used for targeted
230 trimming to the region of interest (ROI) using serial block face scanning electron microscopy
231 (SBF-SEM). Slices were then cut from the exposed surface of the block using a diamond knife in
232 an ultramicrotome, collected onto substrates, and imaged in array tomography format in the
233 SEM, prior to serial spatial metabolic imaging using NanoSIMS, helps us to correlate the
234 metabolite derived label to subcellular structures (Figure 3).

235 NanoSIMS enabled us to measure the $^{13}\text{C}^{14}\text{N}/^{12}\text{C}^{14}\text{N}$ and/or $^{13}\text{C}/^{12}\text{C}$ isotope ratio, derived from
236 [$\text{U-}^{13}\text{C}$] glucose, and the $^{12}\text{C}^{15}\text{N}/^{12}\text{C}^{14}\text{N}$ and/or $^{15}\text{N}/^{14}\text{N}$ isotope ratio, derived from [amide- ^{15}N]
237 glutamine, offering an insight into the metabolic activities in different cells and cellular
238 compartments within the TME²³.

239 ²³**[H3] Quantitation and standards**

240 We would recommend a minimum of 2 biological replicates (mice/tumours) per experimental
241 group for this protocol. The specific number of biological replicates will be dependent on the
242 biological question. In our original paper 2 biological replicates was sufficient to validate our
243 hypothesis because with single cell resolution and relatively large areas covered by correlative
244 light microscopy and SEM, we can analyse multiple cells of interest within the same tissue¹. We
245 prepared consecutive sections on wafer for immediate technical replicates. However, due to
246 the precise nature of the method we did not have any loss of signal and were able to measure
247 the isotope ratios in multiple regions within individual cells, hence it was not necessary to rely
248 on the technical replicates.

249 This method is however not yet capable of absolute quantification of the amount of ¹³C or ¹⁵N
250 and is only a ratio metric comparison. As we are not reporting any type of absolute
251 quantification, the protocol does not require any analytical standards, but should the protocol
252 be adapted to determine the level of a drug, for example, denoted by an isotopic signature,
253 then a matrix matched standard would be required to convert secondary ion count rate into an
254 absolute concentration value.

255 [H3] Method modification and optimisation

256 Adopting this protocol for other biological applications should be straightforward. Optimisation
257 would be required for the accurate detection of the specific labelled metabolites/compounds
258 chosen and the respective cell types of interest using the relevant non-depleting fluorescent-
259 tagged antibodies. This could be done using tissue collected from wild-type mice without
260 tumours to test different labelled compounds and antibody incorporation in the respective

261 tissue of interest. Positive and negative controls can be picked depending on the experiment. In
262 our case for a negative control, we collected a tumour tissue from the MYC-induced liver
263 tumour model without the administration of [$U-^{13}C$] glucose and [amide- ^{15}N]. The negative
264 control was used to establish the ratio prior to analysing the tumours with the labelled glucose
265 and glutamine. In most cases, due to the nature of the method being a comparison of ratios,
266 the positive and negative controls may not be strictly necessary.

267 In the following sections, we describe the methodologies employed in each imaging technique
268 and a step-by-step guide to our multimodal approach.

269

270 **[H2] Expertise needed to implement the protocol**

271 A certain degree of expertise and training is required for work involving animals. The specific
272 licence required depends on the country in which the experiments are performed, and the
273 techniques involved. For example, hydrodynamic tail vein injection described in this case study
274 is a difficult technique to perform and requires considerable effort to become proficient. But
275 this pipeline does not strictly require this, and the methods described here can be easily applied
276 to a wide array of mouse models as well as other *in vivo* studies. Several genetically engineered
277 mouse models such as spontaneous tumour models, for example, do not require any such
278 technical proficiency to generate tumours. Large institutes, universities, and companies have
279 core facilities responsible for the handling and care of experimental animals. Such facilities can
280 help researchers design and set up experiments involving animals.

281 EM is a common method, with robust protocols for embedding and processing. Consequently,
282 2D EM followed by NanoSIMS, which is performed on the very same surface as EM and
283 consequently requires identical preparation, can readily be performed by any researcher or
284 facility with experience in sample preparation for EM. Conversely, the correlation with
285 volumetric fluorescent imaging for ROI selection will require targeting of the ROI with an SBF-
286 SEM, followed by array tomography prior to NanoSIMS acquisition. Both techniques will require
287 collaboration with a well-equipped core facility experienced in volume EM and correlative
288 workflows.

289 Setting up NanoSIMS at any laboratory poses several challenges due to its reliance on expensive
290 instruments and high level of technical proficiency for its operation and maintenance.
291 Consequently, NanoSIMS is typically performed in core facilities or shared instrumentation
292 settings equipped with the requisite expertise and resources. These facilities offer access to
293 cutting-edge instrumentation, expert technical assistance, and comprehensive training to aid
294 researchers in experiment design and data analysis. Collaborating with such core facilities
295 presents a cost-effective and efficient approach, especially for researchers with intermittent
296 requirements for NanoSIMS technology¹⁷.

297 **[H1] Materials**

298 **[H2] Biological materials**

299 • The method for generation of bi-clonal mammary gland tumours has been described in
300 detail previously^{1,16}. Hence here we focus on liver tumour model.

301 • **Mice.** Adult (7- to 9-week-old) male mice of FVB/N strain (RRID:MGI:2160001) from The
302 Francis Crick Institute Biological Research Facility (BRF). All procedures and animal
303 husbandry were carried out in accordance with the UK Home Office, under the Animals
304 (Scientific Procedures) Act 1986, and the Crick Animal Welfare and Ethical Review Body
305 (AWERB), which is delivered as part of the BRF Strategic Oversight Committee (BRF-
306 SOC), under the Project Licence number P609116C5.

307 [H2] Reagents

- Sterile saline solution, 0.9% NaCl (40120975, bioWORLD)
- Isoflurane -Vet 100% w/w Inhalation Vapour, Liquid (Merial, Boehringer Ingelheim)
- DPBS 1x (Gibco)
- Agarose, Low gelling temperature (1002718026, Sigma-Aldrich)
- DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride) (D1306, Invitrogen)
- VALAP - Mixture of Vaseline, Lanolin and Paraffin (1:1:1 w/w/w)
- Leica Microsystems Immersion Oil for Microscopes (12847995, Fisher Scientific)

315 [H3] Isotope labelled nutrients

316 • [U-¹³C] glucose (CLM-1396-PK, Cambridge Isotope Laboratories)
317 • [amide-¹⁵N] glutamine (NLM-557-PK Cambridge Isotope Laboratories).

318 [H3] Plasmids –

- pT3-EF1 α -c-MYC (RRID:Addgene 92046, <https://www.addgene.org/92046/>)

320 • pT3-EF1 α -MCL1 (RRID:Addgene_133299; <https://www.addgene.org/133299/>,
321 RRID:Addgene_117726; <https://www.addgene.org/117726/>)
322 • pCMV-SB (RRID:Addgene_24551, <https://www.addgene.org/24551/>).

323 **[H3] Antibodies –**

324 • CD8a-PE (Thermo Fisher Scientific Cat# 12-0081-82, RRID:AB_465530,
325 https://scicrunch.org/resolver/RRID:AB_465530)
326 • CD3-AF488 (Thermo Fisher Scientific Cat# 53-0032-82, RRID:AB_2848414,
327 https://scicrunch.org/resolver/RRID:AB_2848414)
328 • B220-AF647 (BioLegend Cat# 103202, RRID:AB_312987,
329 https://scicrunch.org/resolver/RRID:AB_312987)
330 • CD68-AF647 (BioLegend Cat# 137003, RRID:AB_2044001,
331 https://scicrunch.org/resolver/RRID:AB_2044001)

332 **[H3] Reagents for EM**

333 **<CRITICAL>** The materials required for preparing these solutions are listed in the next section.

334 • Solution X (Na₂HPO₄•2H₂O; dihydrate solution) stored at 4°C
335 • Solution Y (NaH₂PO₄•H₂O; monohydrate solution) stored at 4°C
336 • 0.1 M phosphate buffer (PB) at pH 7.4
337 • 0.2M phosphate buffer (PB) at pH 7.4
338 • 2% reduced osmium – made fresh
339 • 1% uranyl acetate – stored at 4°C

- 340 • Lead aspartate (pH 5.5) - made fresh
- 341 • 1% thiocarbohydrazide – made fresh
- 342 • 4% EM-grade formaldehyde in 0.1M PB – made fresh
- 343 • 4% EM-grade formaldehyde, 2.5% glutaraldehyde in 0.1M PB – made fresh
- 344 • 3% potassium ferricyanide – stored at 4°C
- 345 • Ethanol dehydration series; 30%, 50%, 70%, 90%, 100% (dry) ethanol
- 346 • Durcupan resin – made fresh
- 347 • 0.03M aspartic acid pH 3.8 – stored at 4°C
- 348 • 1M potassium hydroxide (KOH)

349 [H3] Chemicals for EM

- 350 • 36% EM-grade formaldehyde (F003, TAAB laboratories)
- 351 • 25% glutaraldehyde (G004, TAAB laboratories)
- 352 • di sodium hydrogen phosphate dihydrate ($\text{Na}_2\text{HPO}_4 \bullet 2\text{H}_2\text{O}$; dihydrate) (28029.260, VWR
353 Chemicals)
- 354 • Sodium phosphate monobasic monohydrate ($\text{NaH}_2\text{PO}_4 \bullet \text{H}_2\text{O}$; monohydrate) (102633600,
355 Sigma-Aldrich)
- 356 • 4% osmium tetroxide (O011, TAAB laboratories)
- 357 • Thiocarbohydrazide (TCH) (102053096, Sigma-Aldrich)
- 358 • Uranyl acetate (R1260A, Agar Scientific)
- 359 • Potassium ferricyanide (P018, TAAB laboratories)
- 360 • Distilled water

361 • L-aspartic acid (A4534-100G, Sigma-Aldrich)

362 • Lead (II) nitrate (102475122, Sigma-Aldrich)

363 • Potassium hydroxide (P1767-250G, Sigma-Aldrich)

364 • Ethanol (10680993, Fisher Scientific)

365 **[H3] Durcupan resin components:**

366 • ACM single component A (Sigma Aldrich 44611)

367 • ACM single component B (Sigma Aldrich 44612)

368 • ACM single component C (Sigma Aldrich 44613)

369 • ACM single component D (Sigma Aldrich 44614)

370 **[H2] EQUIPMENT**

371 **[H3] Materials for EM**

372 • Filter units, 500ml (for PB and aspartic acid) (151-4020, Thermo Scientific)

373 • Metal pin (10-006002-50, Labtech)

374 • Sable hairbrushes (AGG3446, Agar Scientific)

375 • Silver epoxy (604057, CW2400 adhesive, Farnell)

376 • Platinum disc target, 57mm dia x 0.1 mm, Coater type 1 (AGB7392, Agar Scientific)

377 • Silicon wafers (G3390, Agar Scientific)

378 • SEM stubs (10-002012-100, Labtech Electron Microscopy)

379 • Eyelash tool (Single eyelash attached to a cocktail stick using nail varnish)

380 • Adhesive carbon tabs (15-000412, Labtech Electron Microscopy)

381 • Aclar sheets (AGL4458, Agar Scientific)

382 **[H3] Consumables and kits**

383 • Endotoxin-free Maxiprep kit (12362, Qiagen)

384 • Pierce concentrator 10K MWCO (88513, Thermo Fisher Scientific)

385 • Insulin syringe 0.5ml, 29G, 12.7mm (BD)

386 • Tail vein catheter (504147, World Precision Instruments)

387 • SuperFrost Plus Adhesion slides (12312148, Fisher Scientific)

388 **[H3] Equipment and imaging systems**

389 • Centrifuge (Fresco 21, Thermo Fisher Scientific)

390 • Vaportec isoflurane vaporiser (Burtons Veterinary, UK)

391 • Aladdin AL-1000 pump (World Precision Instruments)

392 • Vibrating knife ultramicrotome (VT1200S, Leica)

393 • Confocal microscope (Leica, Falcon SP8)

394 • Stereo microscope (MC205C stereo, DMC 4500 Camera, Leica Microsystems)

395 • Ultramicrotome (EM UC7, Leica Microsystems)

396 • Rotary-pumped sputter coater (Q150S, Quorum Technologies, Lewes, UK)

397 • Serial block face scanning electron microscope (SBF-SEM) - consisting of a 3View2XP

398 (Gatan, Pleasanton, CA) attached to a Sigma VP SEM (Zeiss, Oberkochen, Germany) with

399 focal charge compensation (FCC, Zeiss, Oberkochen, Germany)

400 • Histological diamond knife (DiATOME, Nidau, Switzerland)

401 • Quanta 250 FEG SEM (Thermo Fisher Scientific, Waltham MA USA)

- Low voltage high-contrast backscattered electron detector (vCD, Thermo Fisher Scientific, Waltham MA USA)
- NanoSIMS (Cameca NanoSIMS 50L, Cameca/Ametek, Gennevilliers, France)

405 Software

- Photoshop (Adobe Inc., San Jose, CA USA)
- Leica Application Suite X (LAS X) (Leica Microsystems)
- TrackEM2 plugin for Fiji (<https://fiji.sc/>, <https://imagej.net/plugins/trakem2/>)
- Digital Micrograph (version 2.3.2.888, Gatan)
- SBEMImage (<https://github.com/SBEMImage>)²⁴.
- xT Microscope control (version 6.2.8, ThermoFisher Scientific)
- MAPS software (ThermoFisher Scientific)
- OpenMIMS plugin for Fiji (<https://fiji.sc/>, <https://github.com/BWHCNI/OpenMIMS>)
- BigWarp plugin for Fiji (<https://imagej.net/plugins/bigwarp>)²⁵.

415 [H2] Reagent setup

416 [H3] VALAP

417 1. Measure out a blend of petroleum jelly (Vaseline), lanolin, and paraffin in equal parts

418 (1:1:1 w/w/w).

419 2. Heat the mixture in a glass or ceramic container on a hot plate using medium to low

420 heat until completely liquefied.

421 3. Apply the molten wax mixture onto a glass slide; it should smoothly spread and
422 promptly dry.

423 4. If rapid solidification occurs, incorporate additional petroleum jelly and lanolin.

424 5. If slower solidification is observed, add more paraffin.

425 6. VALAP solidifies at room temperature; prior to use, gently warm it on a hot plate at a
426 low setting²⁶.

427 **[H3] Solution X**

428 Dissolve 18.69 g Na₂HPO₄•2H₂O; dihydrate (VWR 28029.260) in 525 ml ddH₂O. Filter, sterilise and
429 store at 4° C. It is stable under these conditions for up to a year.

430 **[H3] Solution Y**

431 Dissolve 13.80 g NaH₂PO₄•H₂O; monohydrate in 500 ml ddH₂O. Filter, sterilise and store at 4° C.
432 It is stable under these conditions for up to a year.

433

434 **[H3] 0.2M PB**

435 Prepare 0.2M PB by mixing:

436 Solution X 202.5 ml

437 Solution Y 47.5 ml

438 Store at 4° C for up to a year

439

440 **[H3] 0.1M PB**

441 Prepare 0.1M PB by mixing:

442 Solution X 202.5 ml

443 Solution Y 47.5 ml

444 ddH₂O 250 ml

445 Store at 4°C for up to a year

446

447 **[H3] 4% formaldehyde in 0.1M PB (Primary fixation)**

448 36% formaldehyde 1.1 ml

449 0.2M PB 5 ml

450 ddH₂O 3.9 ml

451 Make fresh

452 **[H3] 4% formaldehyde, 2.5% glutaraldehyde in 0.1M PB (Secondary fixation)**

453 36% formaldehyde 1.1 ml

454 25% glutaraldehyde 1 ml

455 0.2M PB 5 ml

456 ddH₂O 2.9 ml

457 Make fresh

458 **[H3] 2% reduced osmium (2% OsO₄, 1.5% K₃Fe(CN)₆). Safety is critical.**

459 In a fume hood, mix equal volumes 4% Osmium Tetroxide and 3% Potassium Ferricyanide

460 4% Osmium 5 ml

461 3% Potassium Ferricyanide 5 ml

462 Make fresh

463 **[H3] 1% TCH solution.**

464 Make fresh ~10 ml of 1% TCH solution. You will need approximately:

465 ddH₂O 10 ml

466 Thiocarbohydrazide 0.1 g

467

468 1. Zero balance with an empty tube.

469 2. Transfer tube to a fume hood, then add some thiocarbohydrazide powder to the tube.

470 3. Close the tube, remove from fume hood, and weigh it on the balance.

471 4. If more powder is needed, repeat steps 2-3 (i.e., only opening the tube and handling
472 powder in the fume hood).

473 <CRITICAL> For convenience, rather than weighing out exactly 0.1 g, weigh what you added

474 to the tube and adjust the water accordingly. For example, for 0.11 g of thiocarbohydrazide,

475 use 11 ml of water.

476 5. In the fume hood, add water, close tube.

477 6. Incubate for 1 h, 60°C.

478 7. Swirl to mix every 10 minutes to facilitate dissolving.

479 8. Filter through a 0.22 µm Millipore syringe filter right before use.

480

481 **[H3] 1% aqueous uranyl acetate. Safety is critical.**

482 Make ~50 ml of 1% UA in double distilled water. You will need:

483 ddH₂O 50 ml

484 uranyl acetate 0.5 g

485 1. Zero a balance with an empty 50 ml tube.

486 2. Transfer tube to a fume hood, then add some uranyl acetate powder to the tube.

487 3. Close the tube, remove from fume hood, and weigh it on the balance.

488 4. If more powder is needed, repeat steps 2-3 (i.e., only opening the tube and handling

489 powder in the fume hood).

490 5. In the fume hood, add the appropriate amount of water, close the tube and seal with

491 Parafilm.

492 6. Mix on a vortex for 1-2 min

493 7. Wrap the tube in aluminium foil to protect from light and place the tube on a rolling

494 mixer for 2-3 h, repeating vortex as above every hour or so, until the uranyl acetate is

495 dissolved.

496 8. Store at 4°C. It should be stable for at least 100 days as long as the uranyl acetate stays

497 in solution.

498 **<CRITICAL>** For convenience, rather than weighing out exactly 0.5 g, weigh what you added to

499 the tube and adjust the water accordingly. For example, for 0.46 g of uranyl acetate, use 46 ml

500 of water.

501

502 **[H3] 1M Potassium hydroxide (KOH)**

503 Make 100ml of 1M KOH. You will need:

504 Potassium hydroxide 5.61g

505 ddH₂O 100ml

506 Store at room temperature, it should be stable for a year as long as the Potassium Hydroxide
507 stays in solution.

508

509 **[H3] 0.03M Aspartic acid pH 3.8**

510 Make 250ml of 0.03M aspartic acid pH 3.8. You will need:

511 L-aspartic acid 1g

512 ddH₂O 250ml

513 1. Add aspartic acid powder to water and stir with a magnetic stirrer bar; a small amount
514 will dissolve, which lowers the pH to around 3.

515 2. pH to approximately 3.8 by adding 1 M KOH dropwise.

516 3. This lets more aspartic acid dissolve, which lowers the pH again.

517 4. Wait until the pH stops reducing.

518 5. Then repeat steps 2-4 until certain all the aspartic acid has dissolved.

519 6. pH should now remain stable at 3.8.

520 7. Filter, sterilise and store at 4°C for up to 2 months.

521 **[H3] Lead Aspartate**

522 Make 0.66% lead nitrate in 0.03 M pH 3.8 aspartic acid. You will need:

523 0.03 M pH 3.8 aspartic acid 20 ml

524 lead nitrate 0.132 g

525 1. Zero balance with an empty tube.

526 2. Transfer tube to a fume hood, then add some lead nitrate powder to the tube.

527 3. Close the tube, remove from fume hood, and weigh it on the balance.

528 4. If more powder is needed, repeat steps 2-3 (i.e., only opening the tube and handling
529 powder in the fume hood).

530 5. Transfer to a fume hood and dissolve the lead nitrate in room temperature 0.03 M pH
531 3.8 aspartic acid stock.

532 6. Using a glass pipette, pH to 5.5 dropwise with 1 M KOH, swirling gently to mix after each
533 drop, while checking pH. Check carefully that the solution remains clear, and no
534 precipitate has formed.

535 7. Incubate in glass vial for 30 min 60°C.

536 <CRITICAL> For convenience, rather than weighing out exactly 0.132 g, weigh what you
537 added to the tube and adjust the water accordingly. For example, for 0.130 g of lead nitrate,
538 use 19.70 ml of water (i.e., to make 0.66% w/v).

539 8. Make fresh.

540

541 <CRITICAL> Precipitation can occur easily, more so as pH approaches 5.5; this gives a slightly
542 white, turbid, appearance, rather than the correct, clear liquid. Adding small amounts (1-2
543 drops) of 1 M KOH will cause slight cloudiness, but this can be dissolved by swirling to mix.

544 Adding more 1 M KOH at once can cause precipitation that cannot be re-dissolved. Do not use
545 magnetic stirrer, the slightest bumps can cause precipitation, even at lower pH.

546 <CRITICAL> During incubation at 60°C no precipitation should form. If you notice any
547 precipitation, discard the solution and start again.

548

549 **Durcupan resin**

550 1. Place a stirrer in a plastic beaker.

551 2. Weigh out the amounts below, using 3 ml plastic Pasteur pipettes with the ends cut off

552 (zero after each weighing), in the fume hood. *The range for Component D comes from

553 a protocol of the National Centre of Microscopy and Imaging Research²⁷; larger volumes

554 have been recalculated to give the same range.

Component A (g)	Component B (g)	Component C (g)	Component D (g)
11.4	10	0.3	0.05-0.1*
22.8	20	0.6	0.125-0.175
34.2	30	0.9	0.2-0.25

555

556 3. After adding component D, stir gently by hand to mix the components, then place on a

557 stirrer plate, cover, and stir for at least 10 min at low speed to avoid air bubbles.

558 4. Stop stirring and leave for 5-10 min for air bubbles to dissipate.

559 5. Make fresh.

560 **[H2] Equipment setup**

561 **[H3] Confocal Microscope (Leica, Falcon SP8)**

562 • Switch on the microscope and computer as per standard instructions. Start up the LAS X

563 software with the following configuration: machine with 440 pulsed, microscope –

564 DMi8, Stage calibration enabled.

565 • Set the laser configuration as follows – WLL and 405 lasers set at 70%.

566 • Under the Acquisition panel, set the excitation and emission ranges for the two PMT
567 detectors, HyD1 and HyD3 for imaging DAPI (358-461nm), Alexa Fluor 488 (448-496nm),
568 PE (565-574nm) and Alexa Fluor 647 (650-665nm) respectively.

569 • Use the LAS X navigator to locate and mark the sample boundaries under a 20X air
570 objective (HC PL APO 20x/0.75 IMM CORR CS2).

571 • Utilize the spiral function can be to perform a low-resolution scan to find regions of
572 interest.

573 • Navigate to the focus map feature to mark the different focal points and corresponding
574 Z stack prior to scanning.

575 • Use mosaic merge to stitch the tile scan together to obtain a single overview image of
576 the sample.

577 • When switching to the 63X objective (HC PL APO 63x/1.40 OIL CS2) a drop of immersion
578 oil is applied on the coverslip.

579 **[H3] Serial Block Face Scanning Electron Microscope** (consisting of a 3View2XP (Gatan,
580 Pleasanton, CA) attached to a Sigma VP SEM (Zeiss, Oberkochen, Germany) with focal charge
581 compensation (FCC, Zeiss, Oberkochen, Germany)

582 1. Start Digital micrograph (Gatan) and SmartSEM (Zeiss) softwares.

583 2. Load the sample into the microscope as per instructions.

584 3. Adjust the focal charge compensator (FCC) to optimal position for the sample.

585 4. Pump microscope to vacuum.

586 5. Turn on the SmartSEM (Zeiss) at 2 kV, with an aperture of 30 μm and an FCC level of
587 50%. Use this as a start point and adjust to suit the sample.

588 6. In Digital Micrograph, launch the open-source software SBEMimage.

589 7. Use the Gatan 3view BSD detector to collect back scattered electrons.

590 **[H3] Scanning Electron Microscope (Thermofisher, Quanta 250 FEG SEM)**

591 1. Launch xT microscope control (v6.2.8).

592 2. Load the sample as per manufacturer's instructions.

593 3. Pump microscope to vacuum.

594 4. Turn on the beam at 2.5kV and a spot size of 3. Use this as a start point and adjust to
595 suit the sample.

596 5. Once sample is in focus, launch MAPS software.

597 6. Image the sample using the vCD (Thermofisher) to collect back scattered electrons.

598 **[H3] NanoSIMS (Cameca NanoSIMS 50L)**

599 1. Mount sample (sections on 5mm x 5mm Si chips) onto Harvard holder.

600 2. Load the sample into to the instrument per manufacturer's instructions and analysis

601 3. Pump the chamber to $2-5 \times 10^{-10}$ mbar.

602 4. Set the z-height of the sample stage.

603 5. Implant Cs^+ ions in the region of interest.

604 6. Position the detectors to the correct radii for analysis.

605 7. Measure the pulse height distributions of the electron multiplier (EM) detectors and
606 adjust their voltage gains and thresholds if necessary.

607 8. Examine the detectors further by measuring the C⁻ and CN⁻ count rate on adjacent
608 detectors and use it to measure the ¹³C/¹²C and ¹²C¹⁵N/¹²C¹⁴N isotope ratios. This step is
609 imperative for measurement of accurate isotope ratios.

610 9. Align the secondary column.

611 10. Optimise the Mass Resolving Power (MRP) to ensure high mass resolution.

612 11. Acquire high mass resolution spectra for each mass and carefully select the secondary
613 ion position from those scanned through the exit slit. Select the image acquisition
614 parameters depending upon the required spatial resolution, sensitivity, and mass
615 resolution. Further details can be found in McMahon & Lechene²⁸.

616

617 **[H1] Procedure**

618 <CRITICAL> In this section we will go through the different steps of the protocol shown in the
619 workflow in detail (Fig 3). The section is further subdivided as follows: hydrodynamics-based
620 transfection of DNA in the liver to generate liver tumours (Steps 1-3), antibody clean-up (Steps
621 4-7), stable isotope labelling and in vivo administration of antibodies (Steps 8-12), embedding
622 for EM and immunofluorescence imaging (Steps 13-28), targeted single section large area
623 montaging (Steps 29-41), NanoSIMS acquisition (Steps 42-48) and NanoSIMS analysis (Steps 49-
624 51).

625 **Hydrodynamics-based transfection of DNA in the liver to generate liver tumours**

626 ***Timing 4 weeks***

627 <CRITICAL> Liver tumours were generated as described previously⁷. Hydrodynamic-based
628 transfection was performed as established²², with some variations detailed below.

629 1. Prepare a mixture comprising 5 µg of pT3-EF1α-c-MYC, 5 µg of pT3-EF1α-Mcl1, and 0.2
630 µg of sleeping beauty transposase (SB) plasmid DNA (purified using an Endotoxin-free
631 Maxiprep kit) in a 25:1 ratio diluted in a volume of saline equivalent to 10% of the mice's
632 body weight.

633 <CRITICAL STEP> To counteract MYC-induced apoptosis and enhance the efficiency of MYC-
634 induced tumorigenesis, the ectopic expression of MYC through hydrodynamics-based
635 transfection was combined with MCL1 expression. By carefully titrating the amount of SB used,
636 we ensured a consistent level of integration events and induction of tumorigenesis.

637 2. Put the mice under isoflurane anaesthesia using a Vaportec Isoflurane Vaporiser and
638 inject the mixture into the lateral tail vein of the mice (7- to 9-week-old male FVB/N)
639 within 8 to 12 seconds. Place the mice in a ventilated recovery unit overnight following
640 the procedure.

641 3. Regularly check for the presence of liver tumours by gentle palpitation of the abdominal
642 region of the mice, starting from 2 weeks post injection.

643 • You can identify the liver tumours as hard masses in the soft abdominal area or by a
644 swollen abdomen when the tumour progresses further.

645 • When there is a 20% increase in the normal abdomen diameter it is considered a
646 humane endpoint. Tumours take an average of 3-4 weeks to reach this stage.

647 • Tumours can also be monitored using non-invasive in vivo imaging methods such as
648 ultrasound imaging or MRI (Magnetic Resonance Imaging).

649 Antibody clean-up *Timing 20 minutes*

650 4. Pipette the appropriate volume for 4 µg of each antibody into the concentrator sample

651 chamber of Pierce Concentrator 10K MWCO spin tube.

652 5. Add 500ul of dPBS into the chamber of the spin tube.

653 6. Centrifuge the tube at 15000 x g for 10 minutes at 4°C.

654 7. Discard the flow through and resuspend the purified antibody in the chamber in 40ul of

655 saline for the injection.

656 Stable isotope labelling and in vivo administration of antibodies *Timing 4-5 hours*

657 <**CRITICAL**> The injection of antibodies (step 9) and the initial bolus of the isotope-labelled
658 metabolites (step 11) can be administered as a single injection by mixing both solutions. The
659 advantage of doing this is mainly to reduce the time taken to prepare and administer
660 multiple injections.

661 8. Once liver tumours are detected as described in step 3, weigh the mice and put them
662 under isoflurane anaesthesia to prepare for injection of antibody suspension and
663 isotope-labelled metabolites.

664 9. Cannulate the tail vein and affix the tail catheter in place with an adhesive. Use a 0.5ml
665 insulin syringe to inject the purified antibody suspension from step 7 via tail vein
666 injection by attaching the syringe to the catheter tube

667 10. Prepare a saline solution consisting of both [$U-^{13}C$] glucose (96 mg/ml) and [amide- ^{15}N]
668 glutamine (40 mg/ml).

669 11. Take an appropriate volume of the solution from the previous step for a final
670 concentration of [^{13}C] glucose at 0.442 mg per g of body weight of the mouse and
671 [amide- ^{15}N] glutamine at 0.187 mg per g of body weight. Administer the mice with this
672 initial bolus of the solution with both [^{13}C] glucose and [amide- ^{15}N] glutamine via tail
673 vein injection using a 0.5ml insulin syringe as described in step 9.

674
675 12. Fill a 1 ml insulin syringe with an appropriate volume of the solution from step 10 and set
676 up a 3 h infusion of glucose (0.012 mg per g body weight per minute) and glutamine
677 (0.005 mg per g body weight per minute), maintained at a rate of 0.2 ml h^{-1} on the pump.

678 <**CRITICAL STEP**> Infusions of stable isotope mixture which is performed through a tail vein
679 catheter utilizing the Aladdin AL-1000 pump. The syringe with the labelled metabolites is set
680 up on the pump and the free end of the tail vein catheter tubing is attached to the needle of
681 the syringe. The flow rate and duration is adjusted on the pump. The infusion protocol was
682 established based on prior experiments¹.

683 13. After the end of the infusion, cull the mice by cervical dislocation or other approved S1K
684 methods.

685 14. Dissect out tumours using sterile surgical tools. Cut large tumour tissues into smaller
686 chunks of approximately 1cm in diameter.

687 **Fluorescence imaging and sample preparation for EM Timing 4 days**

688 15. Fix the tumours overnight in 2-5ml (enough to cover the tumour chunks) of freshly
689 prepared 4% paraformaldehyde in 0.1 M PB at pH 7.4 and store them at 4°C.

690 <PAUSE POINT> After overnight fixation the tumours can be transferred to 0.1M PB and stored
691 at 4°C for extended periods.

692 16. Following initial fixation, embed the samples in 2% low melting point agarose in 0.1 M
693 PB. Add enough to cover the entire tumour chunk.

694 17. Use a vibrating knife ultramicrotome with speed of 1 mm/s and an amplitude of 0.75
695 mm, to collect 150 µm thick sections. Remove excess agarose from the sections and
696 store the tissues in a 24-well plate in 0.1 M PB at 4°C.

697 <CRITICAL STEP> A detailed training guide on how to perform the sectioning has been prepared
698 by our team – <https://vimeo.com/763353109>

699 18. Stain the tumour sections with 200 µl DAPI (1:1000 dilution in 0.1M PB – 1µg/mL working
700 concentration) for 30 min. This step can be done in a 24-well plate.

701 19. Transfer the sections onto a glass slide carefully using a paintbrush, coverslip in 0.1M PB
702 and seal the edges with VALAP.

703 <CRITICAL STEP> Be careful not to damage the section when transferring and to avoid air
704 bubbles which could dry out the section. The section must be in 0.1M PB during the whole
705 imaging session. Take a picture of the orientation of the section on the slide which can help
706 with orientation of the image under the microscope.

707 20. Image the whole section in a single plane with a Leica SP8 Falcon confocal microscope at
708 a 20X magnification, the tissue boundaries and focal plane can be determined using the
709 LAS X navigator as described in the equipment setup.

710 21. With the help of the 20X overview scan, choose appropriate regions of interest (ROI)
711 within the tumour section and image a Z-stack of approximately 70 µm depth with a

712 step-size of 2.75 μm at 63X magnification over an area of approx. 1.5 mm^2 . Note the
713 location coordinates for each of the ROIs (regions of interest) within the tumour
714 precisely.

715 22. After imaging the sections, gently scrape the VALAP from the edges and float the
716 coverslip off by immersing the slide in 0.1M PB.

717 23. Carefully remove the imaged sections using a paintbrush and transfer them back into the
718 24-well plate with fresh 0.1M PB. The sections can then be embedded using a protocol
719 adapted from the NCMIR method²⁷.

720 24. Post-fix sections in 4% paraformaldehyde/ 2.5% glutaraldehyde in 0.1 M PB pH 7.4 for 1
721 h at room temperature.

722 25. Wash sections in 0.1 M PB (5 x 3 min) before post-fixing in 2% reduced osmium (2%
723 osmium tetroxide / 1.5% potassium ferricyanide) at 4°C for 1 h.

724 26. Wash the sections in dH₂O (5 x 3 min), stain in 1% thiocarbohydrazide for 20 min at room
725 temperature.

726 27. Wash the sections again in dH₂O (5 x 3 min) and stain in 2% osmium tetroxide for 30
727 mins at room temperature.

728 28. Wash the samples once more in dH₂O (5 x 3 min) and incubate overnight in 1% uranyl
729 acetate at 4°C.

730 29. The following day wash the sections in dH₂O (5 x 3 min) and stain en bloc with lead
731 aspartate (pH 5.5) for 30 min at 60°C

732 <CRITICAL STEP> It is essential that this step is performed as described in order to get
733 enough contrast in the SBF-SEM).

734 30. After a final wash in dH₂O (5 x 3 min), dehydrate sections using a graded series of ethanol
735 (20%, 50%, 75%, 90%, 100% x 2, 20 min each).

736 31. Perform infiltration with Durcupan resin and ethanol (1:1 resin: ethanol) overnight and
737 then with 100% Durcupan resin for 24 h.

738 32. Flat embed the sections between two sheets of aclar and place in an oven to polymerise
739 at 60°C for 48 h.

740 <**CRITICAL STEP**> If Samples are not flat embedded, you will not be able to follow the
741 microscope sample preparation steps.

742 **Targeted single section large area montaging**

743 ***Timing 2-3 days (depending on depth of area of interest)***

744 33. Remove the polymerised sections from the Aclar and prepare blocks from the ROI.

745 <**CRITICAL STEP**> The ROI is identified by aligning the overview of 63X confocal image of
746 the whole section to an overview image of the now embedded section, acquired using a
747 stereo microscope in Photoshop. This ROI includes the cells of interest marked on the
748 confocal image using the respective markers: CD3-AF488 for T cells, CD8a-PE for
749 cytotoxic T cells and B220-AF647 for B cells.

750 34. Use a razor blade (**SHARPS RISK**) to carefully remove the identified area from the resin
751 with approximately 250 µm of excess resin on each side.

752 35. Mount the excised block on a metal pin using silver epoxy which is polymerised at 60°C
753 for 1 h (CW2400, Circuit works)².

754 36. Remove the sample from the oven and trim any excess resin and silver epoxy using a
755 glass knife on an ultramicrotome (EM UC7).

756 <**CRITICAL STEP**> The resin block needs to be shaped into a square with one corner removed so
757 that it is asymmetric, to aid in orientation of the block in the serial block face scanning electron
758 microscope (SBF-SEM).

759 37. Finally, trim the block face at ultramicrotome position 0,0,0, until the tissue is reached.

760 <**CRITICAL STEP**> Cutting empty resin from surface of block is essential to reduce time on
761 the microscope. It also reduces charge build up at the start of the microscope run.

762 38. Sputter coat the block with 10 nm of platinum (Q150S, Quorum Technologies, Lewes, UK)

763 <**CRITICAL STEP**> It is important to sputter coat the block, because it helps dissipate charge
764 build up on samples. It also makes loading of samples into SBF-SEM easier, as it gives the
765 sample surface a reflective surface for knife alignment).

766 39. Load the block into the SBF-SEM, which consists of a 3View2XP attached to a Sigma VP
767 SEM with focal charge compensation (FCC). The SBF-SEM is used as a 'smart trimming'
768 tool, allowing for the visual assessment of the tissue structure in real time.

769 40. Acquire backscattered electron detector images (3View detector, Gatan, Pleasanton, CA)
770 and match with the structures imaged in the 63X confocal Z-stack.

771 41. When the Z-plane in the SBF-SEM contains the specific ROI, remove the sample from the
772 microscope, re-trim the block using a glass knife to a sub-area of the ROI approximately
773 400 µm by 200 µm and 200 nm sections from the block face using an ultramicrotome
774 (EM UC7) and a 6 mm histological diamond knife.

775 <**CRITICAL STEP**> The SBF-SEM block shape is not optimal for regular sectioning methods. To
776 ensure a clean collection of the region of interest, it is important to retrim the block.

777 42. Carefully deposit the sections onto silicon wafers using an eyelash tool and dry them on a
778 hotplate at 70°C for 10 min.

779 43. Mount the silicon wafers onto SEM stubs using adhesive carbon tabs and load into a
780 Quanta FEG 250 SEM.

781 44. Acquire tiled images of the whole section using MAPS software (version 1.1.8.603) with a
782 low voltage high-contrast backscattered electron detector. Images are acquired using an
783 accelerating voltage of 2.5 kV, a spot size of 3, a dwell time of 5 ms, a working distance of
784 6 mm and a pixel resolution of 10 nm.

785 45. Export individual images from the tiled sequence to tiff and align into a single image
786 using the TrackEM2 plugin in Fiji 64²⁹.

787 <CRITICAL> A video guide prepared by our team for the workflow up to the SBF-SEM smart
788 trimming is available for further reference here – <https://vimeo.com/687907249>.

789 **NanoSIMS acquisition**

790 ***Timing 1 week***

791 <CRITICAL> Both the exported single image and the corresponding resin section on a silicon
792 wafer can now be sent to guide NanoSIMS imaging and analysis. Since NanoSIMS analysis is
793 destructive, it is essential that sections were thick enough to survive the entire analysis, yet still
794 provide adequate counting statistics. Comprehensive details on sample preparation and data
795 acquisition can be found in the literature²⁸ and is summarised here. The samples are stable at
796 room temperature at this stage and can be stored indefinitely before analysis.

797 46. Position the fixed detector 7 on the NanoSIMS 50L to measure ^{32}S . This will fix the value
798 of the magnetic field in the mass analyzer.

799 47. Move detectors 1-6 to positions where they will measure ^{12}C , ^{16}O , $^{12}\text{C}^{14}\text{N}$, $^{12}\text{C}^{15}\text{N}$ and ^{31}P .

800 48. Operate the instrument in “Combined Analysis” mode to enable the additional detection
801 of $^{13}\text{C}^{14}\text{N}$.

802 49. Acquire the mass images at a $25\text{ }\mu\text{m} \times 25\text{ }\mu\text{m}$ field width with a $150\text{ }\mu\text{m}$ D1 aperture (D1-
803 4) to provide a mosaic correlating with regions previously analysed by fluorescence and
804 scanning electron microscopy.

805 50. Load the sample into the UHV (1.5×10^{-10} torr) analysis chamber and move it to a
806 location where it may be imaged optically using a CCD camera. The images provided by
807 this camera can show structure from the sections that can easily be correlated with the
808 corresponding SEM images of the same sections (Figure 4A - optical image from
809 NanoSIMS and Figure 4B - SEM images).

810 51. The position of the ion beam for eventual NanoSIMS imaging is displayed as a cross on
811 the optical image. Move the stage from its current position to that where the NanoSIMS
812 imaging will take place.

813 52. Examine higher resolution SEM images with the cells of interest (B cells and CD8 T-cells)
814 identified by confocal fluorescence microscopy. Tumour cells demarcated based on their
815 cellular morphology are denoted³⁰, as in Figure 2A.

816 53. Measure the Pulse Height Distributions (PHDs) of the electron multiplier (EM) detectors
817 to ensure that their response is equivalent.

- These should be measured on a section of tissue away from the actual area of interest.
- Ensure that the PHDs are measured on samples that have been fully implanted, that is, the count rate measured on the detector has plateaued at a maximum value and remains constant.
- After this calibration is complete, the count rate should be the same on adjacent detectors used to measure specific isotope ratios.

825 <CRITICAL STEP> Measuring PHDs is essential to allow measurement of accurate isotope ratios.

826 54. Align the secondary ion beam to ensure maximum signal reaches the detectors.

827 55. Use the quadrupole lens (Q) and the LF4 slit lens to optimize the mass resolving power in
828 the high mass resolution spectra (HMRs) to ensure the correct mass peaks are measured
829 without contributions from potential neighbouring mass interferences (eg. ^{13}C and
830 $^{12}\text{C}^1\text{H}$).

831 56. Select image acquisition parameters: pixel resolution, dwell time, and number of planes.

832 • The pixel size is selected to obey the rule of thumb that the spot size of the primary ion
833 beam should be approximately twice the pixel size to prevent excessive over-and under
834 sampling.

835 • Multiple plane image scans provide a means for drift correction and sufficient counting
836 statistics to improve precision in the ratio value. The minimum number of planes
837 selected for the example experiments was 50 and the maximum, 150.

838 <**CRITICAL STEP**> It is essential to optimize the mass resolution, as contributions from mass
839 interferences to the heavy isotope label masses can produce erroneously and misleadingly
840 high isotope ratio values.

841

842 **NanoSIMS analysis**

843 ***Timing variable***

844 57. Extract the processed images and quantitative data using the OpenMIMS plug-in for
845 Fiji/ImageJ³¹.

846 <**CRITICAL**> NanoSIMS raw data consists of mass resolved isotopic images from the eight
847 defined masses. Carbon and nitrogen isotope images are derived from the $^{13}\text{C}^{14}\text{N}$, $^{12}\text{C}^{14}\text{N}$,
848 and $^{12}\text{C}^{15}\text{N}$ images as $^{13}\text{C}^{14}\text{N}/^{12}\text{C}^{14}\text{N}$ and $^{12}\text{C}^{15}\text{N}/^{12}\text{C}^{14}\text{N}$, respectively.

849 58. Draw ROIs within the nucleus and cytoplasm of the different cell types (B cells and CD8 T-
850 cells) using the SEM image and $^{12}\text{C}^{14}\text{N}$ image as a guide. Figure 5 illustrates an example of
851 ROI selection from a B-cell identified in the SEM image (Figure 5A). This image shows
852 excellent tissue structure and allows us to define ROIs without any bias that may be
853 elicited by the isotope ratio image (Figure 5B and C).

854 59. From each ROI, extract the total counts for all mass images, as well as the isotope ratios.
855 The isotope ratio values can be extracted in two ways (using a nitrogen isotope ratio as
856 an example):

857 • you can calculate the isotope ratio at each pixel within the measured ROI and the mean
858 value, or

859 • the sum of the $^{12}\text{C}^{15}\text{N}$ and $^{12}\text{C}^{14}\text{N}$ counts over all pixels within the ROI and derive a
860 simple ratio of those values.

861 These values should be similar unless the ratio values are disparately and heterogeneously
862 distributed throughout the ROI, or the count rate of the heavy isotope is low.

863 **Timing**

864 **Hydrodynamics-based transfection of DNA in the liver to generate liver tumours**

865 Steps 1-2, hydrodynamics-based tail vein injection ~2 h

866 Step 3, monitoring for liver tumours, 3-4 weeks

867 **Antibody clean-up**

868 Steps 4-7, ~20 min

869 **Stable isotope labelling and in vivo administration of antibodies**

870 Steps 8-10, administration and preparing for infusion ~1 h

871 Steps 11-14, infusion and tissue collection ~4 h

872 **Embedding for EM and immunofluorescence imaging**

873 Steps 15, overnight fixation ~12 h

874 Steps 16 & 17, vibratome sectioning ~2 h

875 Steps 18-21, confocal imaging ~4h

876 Steps 22-32, embedding ~3 d

877 **Targeted single section large area montaging**

878 Steps 33-45, SBF-SEM smart trimming, 2-3 d depending on area of interest

879 **NanoSIMS acquisition**

880 Steps 46-56, can roughly take maximum of 1 week, depending on the size and number of the
881 regions

882 **NanoSIMS analysis**

883 Steps 57-59, variable depending on the expertise of the user.

884 **Troubleshooting**

885 Troubleshooting advice can be found in Table 2.

886 **Table 2 Troubleshooting**

Step	Problem	Possible reason	Possible solution
18	DAPI signal is not detected or is present on the edges of the tissue	The DAPI did not penetrate through the section	Consider longer incubation with DAPI on a gentle shaker
39	Still seeing charge in the sample despite setting up the FCC	FCC is not positioned correctly for the ROI	Re-vent the microscope and adjust the positioning of the FCC in relation to the ROI.
40	Signal on the backscatter detector is lower than expected and imaging is difficult	Contrast in the sample is not sufficient	Adjust staining steps on the embedding process to increase contrast in the sample.
53	Count rate not the same as measured on two adjacent detectors to be used to derive isotope ratios	C4X deflector not set properly.	Scan voltage across C4X while simultaneously measuring all mass signals. Set C4X voltage value where it is situated on the plateau for ALL masses.

			It does not necessarily need to be centered within the plateau.
55	Unable to measure natural isotope ratio values on control sample.	Poor mass resolution, detectors not properly calibrated, C4X deflector not set properly.	Check C4X deflector value first as above as it is a quick test and could be the solution. Recheck PHDs as per step 46. Consider using a narrower entrance slit and/or aperture slit.

887

888 **Anticipated results**

889 The results from the NanoSIMS analysis gives you the measure of the heavy isotope to natural
 890 isotope ratio. The ratios can be measured for each selected ROI within a selected region of a
 891 cell or the whole cell. In Keruzaler at al¹ $^{12}\text{C}^{15}\text{N}/^{12}\text{C}^{14}\text{N}$ isotope ratio derived from [amide-¹⁵N]
 892 glutamine and the $^{13}\text{C}^{14}\text{N}/^{12}\text{C}^{14}\text{N}$ isotope ratio derived from [U-¹³C] glucose were measured for
 893 each cell in either red or green clone of mixed-clone mammary gland tumours demonstrating
 894 strong [amide-¹⁵N] labelling in nucleoli, consistent with glutamine's role in nucleotide
 895 biosynthesis, and higher [U-¹³C] labelling in the cytosol, reflecting glucose's role as a carbon
 896 donor. Notably, green clones showed significantly greater incorporation of both glucose and
 897 glutamine labels than red clones, even in closely intermingled tumour regions¹. In the liver
 898 tumour experiment $^{12}\text{C}^{15}\text{N}/^{12}\text{C}^{14}\text{N}$ isotope ratio derived from [amide-¹⁵N] glutamine and the
 899 $^{13}\text{C}^{14}\text{N}/^{12}\text{C}^{14}\text{N}$ isotope ratio derived from [U-¹³C] glucose were measured for ROIs within the
 900 nuclear and cytoplasmic components for the different cell types (B-cells and CD8 T-cells).
 901 As described in the previous section (step 51) the sum of counts for each of the following
 902 isotopes, $^{12}\text{C}^{15}\text{N}$, $^{12}\text{C}^{14}\text{N}$, $^{13}\text{C}^{14}\text{N}$ and $^{12}\text{C}^{14}\text{N}$, per pixel within each of the ROIs are calculated. A

903 simple ratio of $^{12}\text{C}^{15}\text{N}/^{12}\text{C}^{14}\text{N}$ and $^{13}\text{C}^{14}\text{N}/^{12}\text{C}^{14}\text{N}$ is obtained for the nuclear and cytoplasmic ROIs
904 of B-cells and CD8 T-cells (Figure 6). Similar results can also be obtained for other cellular
905 compartments such as mitochondria, nuclear membrane, etc and other nutrients labelled with
906 stable isotopes if the corresponding ROIs can be traced using SEM image and natural
907 abundances isotope image as a guide to identify the correct components. For measuring the
908 ratios in other cell types the respective fluorescent-tagged antibodies need to be administered.
909 We have successfully tested antibodies for macrophages and neutrophils. Although the major
910 limitation of these results is that it does not provide an absolute quantification of the amount
911 of ^{13}C or ^{15}N and is only a comparison of the ratios of $^{12}\text{C}^{15}\text{N}/^{12}\text{C}^{14}\text{N}$ and $^{13}\text{C}^{14}\text{N}/^{12}\text{C}^{14}\text{N}$, it allows
912 us to precisely trace the fate of any stable isotope labelled nutrient at a subcellular level.

913

914 **Data Availability**

915 The raw images associated with the SEM and NanoSIMS for the different cell types (Figure 2)
916 are available at <https://doi.org/10.25418/crick.24989841>.

917

918 **References**

- 919 1. Kreuzaler, P. *et al.* Vitamin B5 supports MYC oncogenic metabolism and tumor progression in
920 breast cancer. *Nat Metab* **5**, 1870–1886 (2023).
- 921 2. MacLachlan, C., Sahlender, D. A., Hayashi, S., Molnár, Z. & Knott, G. Block Face Scanning Electron
922 Microscopy of Fluorescently Labeled Axons Without Using Near Infra-Red Branding. *Front
923 Neuroanat* **12**, (2018).

924 3. Fearns, A., Greenwood, D. J., Rodgers, A., Jiang, H. & Gutierrez, M. G. Correlative light electron
925 ion microscopy reveals in vivo localisation of bedaquiline in *Mycobacterium tuberculosis*–
926 infected lungs. *PLoS Biol* **18**, e3000879 (2020).

927 4. de Boer, P., Hoogenboom, J. P. & Giepmans, B. N. G. Correlated light and electron microscopy:
928 ultrastructure lights up! *Nat Methods* **12**, 503–513 (2015).

929 5. Arlauckas, S. P. *et al.* In vivo imaging reveals a tumor-associated macrophage–mediated
930 resistance pathway in anti–PD-1 therapy. *Sci Transl Med* **9**, (2017).

931 6. Greenwood, D. J. *et al.* Subcellular antibiotic visualization reveals a dynamic drug reservoir in
932 infected macrophages. *Science* (1979) **364**, 1279–1282 (2019).

933 7. Méndez-Lucas, A. *et al.* Identifying strategies to target the metabolic flexibility of tumours. *Nat
934 Metab* **2**, 335–350 (2020).

935 8. Quinn, A. *et al.* Host-derived organic acids enable gut colonization of the honey bee symbiont
936 *Snodgrassella alvi*. *Nature Microbiology* 2024 **9**:2 **9**, 477–489 (2024).

937 9. Lechene, C. P., Luyten, Y., McMahon, G. & Distel, D. L. Quantitative Imaging of Nitrogen Fixation
938 by Individual Bacteria Within Animal Cells. *Science* (1979) **317**, 1563–1566 (2007).

939 10. Loussert-Fonta, C. *et al.* Correlation of fluorescence microscopy, electron microscopy, and
940 NanoSIMS stable isotope imaging on a single tissue section. *Commun Biol* **3**, 362 (2020).

941 11. Argüello, R. J. *et al.* SCENITH: A Flow Cytometry-Based Method to Functionally Profile Energy
942 Metabolism with Single-Cell Resolution. *Cell Metab* **32**, 1063-1075.e7 (2020).

943 12. Hartmann, F. J. *et al.* Single-cell metabolic profiling of human cytotoxic T cells. *Nat Biotechnol* **39**,
944 186–197 (2021).

945 13. Passarelli, M. K. *et al.* The 3D OrbiSIMS—label-free metabolic imaging with subcellular lateral
946 resolution and high mass-resolving power. *Nat Methods* **14**, 1175–1183 (2017).

947 14. Kern, C. *et al.* Orbi-SIMS Mediated Metabolomics Analysis of Pathogenic Tissue up to Cellular
948 Resolution. *Chemistry–Methods* (2024) doi:10.1002/cmtd.202400008.

949 15. Yan, X. *et al.* Cell-Type-Specific Metabolic Profiling Achieved by Combining Desorption
950 Electrospray Ionization Mass Spectrometry Imaging and Immunofluorescence Staining. *Anal
951 Chem* **92**, 13281–13289 (2020).

952 16. Kreuzaler, P. *et al.* Heterogeneity of Myc expression in breast cancer exposes pharmacological
953 vulnerabilities revealed through executable mechanistic modeling. *Proc Natl Acad Sci U S A* **116**,
954 22399–22408 (2019).

955 17. Siuzdak, G. Subcellular quantitative imaging of metabolites at the organelle level. *Nature
956 Metabolism* 2023 **5**:9 **5**, 1446–1448 (2023).

957 18. Pfister, D. *et al.* NASH limits anti-tumour surveillance in immunotherapy-treated HCC. *Nature
958* **592**, 450–456 (2021).

959 19. Kotsiligi, E. *et al.* Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-
960 independently and contribute to fibrosis by IgA-FcR signalling. *J Hepatol* **79**, 296–313 (2023).

961 20. Garnelo, M. *et al.* Interaction between tumour-infiltrating B cells and T cells controls the
962 progression of hepatocellular carcinoma. *Gut* **66**, 342–351 (2017).

963 21. Yuneva, M. O. *et al.* The Metabolic Profile of Tumors Depends on Both the Responsible Genetic
964 Lesion and Tissue Type. *Cell Metab* **15**, 157–170 (2012).

965 22. Tao, J. *et al.* Distinct anti-oncogenic effect of various microRNAs in different mouse models of
966 liver cancer. *Oncotarget* **6**, 6977–6988 (2015).

967 23. Lechene, C. *et al.* High-resolution quantitative imaging of mammalian and bacterial cells using
968 stable isotope mass spectrometry. *J Biol* **5**, 20 (2006).

969 24. Titze, B., Genoud, C. & Friedrich, R. W. SBEMimage: Versatile Acquisition Control Software for
970 Serial Block-Face Electron Microscopy. *Front Neural Circuits* **12**, (2018).

971 25. Bogovic, J. A., Hanslovsky, P., Wong, A. & Saalfeld, S. Robust registration of calcium images by
972 learned contrast synthesis. in *2016 IEEE 13th International Symposium on Biomedical Imaging*
973 (ISBI) 1123–1126 (IEEE, 2016). doi:10.1109/ISBI.2016.7493463.

974 26. Valap for agar mounts. *Cold Spring Harb Protoc* **2010**, pdb.rec12380 (2010).

975 27. Deerinck, T. *et al.* NCMIR methods for 3D EM: a new protocol for preparation of biological
976 specimens for serial block face scanning electron microscopy. (2010).

977 28. McMahon, G. & Lechene, C. P. High-Resolution Multi-Isotope Imaging Mass Spectrometry (MIMS)
978 Imaging Applications in Stem Cell Biology. *Curr Protoc* **1**, (2021).

979 29. Cardona, A. *et al.* TrakEM2 Software for Neural Circuit Reconstruction. *PLoS One* **7**, e38011
980 (2012).

981 30. de Senneville, B. D. *et al.* Deciphering tumour tissue organization by 3D electron microscopy and
982 machine learning. *Commun Biol* **4**, 1390 (2021).

983 31. Schindelin, J. *et al.* Fiji: an open-source platform for biological-image analysis. *Nat Methods* **9**,
984 676–682 (2012).

985

986 **Acknowledgements**

987 This work was supported by the Francis Crick Institute, which receives its core funding from
988 Cancer Research UK, the UK Medical Research Council and the Wellcome Trust FC001223
989 (M.Y.); by the CRUK Grand Challenge Award 2015 C57633/A25043 (J.B. & M.Y.). We would like

990 to thank all the animal technicians from the Francis Crick Institute's Biological Research Facility
991 for their dedicated work. LLMs (Microsoft Editor, ChatGPT & Grammarly) were solely used for
992 grammar checks and reformatting purposes during the writing of this manuscript.

993

994 **Author Contributions**

995 S.V.V., P.K., C.M.L and G.M. developed the protocol with critical input from M.Y., L.C. and J.B.
996 The paper was written by S.V.V., P.K., C.M.L. and G.M. Further edits and suggestions for the
997 manuscript were provided by G.G., L.C. and M.Y. The animal experiments and confocal
998 microscopy imaging was performed by S.V.V. The sample preparation and EM imaging was
999 carried out by C.M.L. All the NanoSIMS experiments and data analysis were performed by G.G.
1000 and G.M.

1001

1002 **Author Information**

1003 These authors contributed equally: Sharavan Vishaan Venkateswaran, Peter Kreuzaler.

1004 **Authors and Affiliations**

1005 **The Francis Crick Institute, London, UK**

1006 Sharavan Vishaan Venkateswaran, Peter Kreuzaler, Catherine MacLachlan, Lucy Collinson &
1007 Mariia Yuneva

1008 **The National Physical Laboratory, Teddington, UK**

1009 Gina Greenidge, Greg McMahon & Josephine Bunch

1010 **Corresponding authors**

1011 Correspondence to Sharavan Vishaan Venkateswaran, Peter Kreuzaler or Mariia Yuneva.

1012

1013 **Related links**

1014 **Key references using this protocol [AU: You can add up to 5 primary research papers where**
1015 **the protocol has been used.]**

1016 de Boer, P., Hoogenboom, J. P. & Giepmans, B. N. G. Correlated light and electron microscopy:
1017 ultrastructure lights up! *Nat Methods* 12, 503–513 (2015): <https://doi.org/10.1038/nmeth.3400>

1018 Lechene, C. P., Luyten, Y., McMahon, G. & Distel, D. L. Quantitative Imaging of Nitrogen Fixation
1019 by Individual Bacteria Within Animal Cells. *Science* (1979) 317, 1563–1566 (2007):
1020 <https://www.science.org/doi/10.1126/science.1145557>

1021 Greenwood, D. J. et al. Subcellular antibiotic visualization reveals a dynamic drug reservoir in
1022 infected macrophages. *Science* (1979) 364, 1279–1282 (2019):
1023 <https://www.science.org/doi/10.1126/science.aat9689>

1024 **Key data used in this protocol**

1025 Kreuzaler, P. et al. Vitamin B5 supports MYC oncogenic metabolism and tumor progression in breast
1026 cancer. *Nat Metab* 5, 1870–1886 (2023): <https://doi.org/10.1038/s42255-023-00915-7>

1027

1028 **FIGURES**

1029 Figure 1: Using correlative fluorescence microscopy, EM and NanoSIMS analysis to evaluate
1030 glucose and glutamine catabolism in specific cells of bi-clonal mammary gland tumours. (A)
1031 Schematic of inducible and traceable mouse model of heterogeneity in breast cancer and
1032 experimental workflow used by Kreuzaler et al¹. (B) Representative panel of region of interest
1033 in the bi-clonal tumour with red clones, green clones and macrophages (CD68) identified with

1034 confocal fluorescence image analysis (IF). (C) SEM and correlative NanoSIMS nitrogen/carbon
1035 isotope ratio images of region of interest with tumour cells and macrophage (yellow ROI).
1036 Isotope ratio images are displayed as a hue saturation intensity (HSI) transformation. The blue
1037 hue represents the natural abundance ratios which are 0.37% and 1.1% respectively, while pink
1038 hue represents a value of twice the natural ratio in the $^{12}\text{C}^{15}\text{N}/^{12}\text{C}^{14}\text{N}$ and $^{13}\text{C}^{14}\text{N}/^{12}\text{C}^{14}\text{N}$ HSI
1039 image. Figure adapted from Kreuzaler et al¹.

1040 Figure 2: Immunofluorescence, high resolution SEM and correlative NanoSIMS of immune cells
1041 in the TME of MYC-induced liver tumours. (A) SEM images with cells of interest (B cells – blue
1042 ROI, T cells – red ROI, tumour cells – green ROI) identified by confocal fluorescence analysis and
1043 correlative NanoSIMS ($^{12}\text{C}^{15}\text{N}/^{12}\text{C}^{14}\text{N}$) of the B cell and T cell displayed as isotope ratio images.

1044 Isotope ratio images are displayed as a hue saturation intensity (HSI) transformation. The blue
1045 hue represents the natural abundance ratios which are 0.37% and 1.1% respectively, while pink
1046 hue represents a value of twice the natural ratio in the $^{12}\text{C}^{15}\text{N}/^{12}\text{C}^{14}\text{N}$ HSI image. (B)
1047 Representative panel of the same B cells (B220) and T cells (CD8a) identified with confocal
1048 fluorescence image analysis, SEM and correlative NanoSIMS nitrogen/carbon isotope ratio
1049 images. [Au: Looks good to me. It is difficult for me to read the numbers on the colour scale
1050 bar.]

1051 Figure 3: Flow diagram showing the steps of the multimodal imaging pipeline (Created with
1052 BioRender.com). [Au: Looks good to me.]

1053 Figure 4: Correlating SEM images for NanoSIMS acquisition. (A) SEM image acquired at high
1054 pixel resolution enabling easy digital zooming for fine detail of tissue structure. (B)

1055 Corresponding optical image obtained using NanoSIMS CCD camera showing microtomed thin
1056 sections and structure within. **[Au: Looks good to me.]**

1057 Figure 5: Example of ROI selection for quantitative analysis. (A) SEM image showing a previously
1058 identified B-cell. (B) $^{12}\text{C}^{14}\text{N}$ NanoSIMS image showing ROIs defined in nucleus of B-cell (green
1059 ROIs) and cytoplasm (red ROIs). Similar ROIs are shown for a cancer cell in top right of image.
1060 (C) Corresponding nitrogen isotope ratio image. Isotope ratio images displayed as a hue
1061 saturation intensity (HSI) transformation. The blue hue represents the natural abundance ratios
1062 which are 0.37% and 1.1% respectively, while pink hue represents a value of twice the natural
1063 ratio in the $^{12}\text{C}^{15}\text{N}/^{12}\text{C}^{14}\text{N}$ HSI image. **[Au: Looks good to me.]**

1064 Figure 6: Enrichment of stable isotopes within the intracellular compartments of B cells and CD8
1065 T cells. (A) Comparison of $^{12}\text{C}^{15}\text{N}/^{12}\text{C}^{14}\text{N}$ isotope ratio of ROIs from the nucleus (n=15 ROIs), (B)
1066 $^{13}\text{C}^{14}\text{N}/^{12}\text{C}^{14}\text{N}$ isotope ratio of ROIs from the nucleus (n=15 ROIs), (C) $^{12}\text{C}^{15}\text{N}/^{12}\text{C}^{14}\text{N}$ isotope ratio
1067 of ROIs from the cytoplasm (n=20 ROIs) and (D) $^{13}\text{C}^{14}\text{N}/^{12}\text{C}^{14}\text{N}$ isotope ratio of ROIs from the
1068 cytoplasm of B cells and CD8 T cells. Statistical significance was assessed by unpaired t-test.
1069 (n=20 ROIs, mean +/- SD, **p<0.01, ****p<0.0001).

1070